Veracyte Inc (VCYT)
38.94
-0.26
(-0.66%)
USD |
NASDAQ |
Nov 21, 16:00
38.95
+0.01
(+0.03%)
Pre-Market: 20:00
Veracyte Enterprise Value: 2.744B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.744B |
| November 20, 2024 | 2.764B |
| November 19, 2024 | 2.760B |
| November 18, 2024 | 2.571B |
| November 15, 2024 | 2.511B |
| November 14, 2024 | 2.597B |
| November 13, 2024 | 2.789B |
| November 12, 2024 | 2.690B |
| November 11, 2024 | 2.740B |
| November 08, 2024 | 2.553B |
| November 07, 2024 | 2.620B |
| November 06, 2024 | 2.562B |
| November 05, 2024 | 2.510B |
| November 04, 2024 | 2.437B |
| November 01, 2024 | 2.385B |
| October 31, 2024 | 2.340B |
| October 30, 2024 | 2.438B |
| October 29, 2024 | 2.390B |
| October 28, 2024 | 2.370B |
| October 25, 2024 | 2.285B |
| October 24, 2024 | 2.266B |
| October 23, 2024 | 2.241B |
| October 22, 2024 | 2.252B |
| October 21, 2024 | 2.292B |
| October 18, 2024 | 2.395B |
| Date | Value |
|---|---|
| October 17, 2024 | 2.385B |
| October 16, 2024 | 2.416B |
| October 15, 2024 | 2.366B |
| October 14, 2024 | 2.355B |
| October 11, 2024 | 2.362B |
| October 10, 2024 | 2.227B |
| October 09, 2024 | 2.199B |
| October 08, 2024 | 2.320B |
| October 07, 2024 | 2.351B |
| October 04, 2024 | 2.271B |
| October 03, 2024 | 2.281B |
| October 02, 2024 | 2.345B |
| October 01, 2024 | 2.293B |
| September 30, 2024 | 2.364B |
| September 27, 2024 | 2.358B |
| September 26, 2024 | 2.338B |
| September 25, 2024 | 2.326B |
| September 24, 2024 | 2.355B |
| September 23, 2024 | 2.396B |
| September 20, 2024 | 2.439B |
| September 19, 2024 | 2.472B |
| September 18, 2024 | 2.357B |
| September 17, 2024 | 2.400B |
| September 16, 2024 | 2.347B |
| September 13, 2024 | 2.293B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
643.66M
Minimum
Mar 18 2020
5.083B
Maximum
Feb 09 2021
1.850B
Average
1.671B
Median
Jun 23 2023
Enterprise Value Benchmarks
| Fonar Corp | 41.17M |
| XWELL Inc | 0.1013M |
| ProPhase Labs Inc | 35.22M |
| Applied DNA Sciences Inc | -8.969M |
| OncoCyte Corp | 41.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 15.16M |
| Revenue (Quarterly) | 115.86M |
| Total Expenses (Quarterly) | 103.19M |
| EPS Diluted (Quarterly) | 0.19 |
| Gross Profit Margin (Quarterly) | 68.19% |
| Profit Margin (Quarterly) | 13.08% |
| Earnings Yield | -0.39% |
| Operating Earnings Yield | 0.37% |
| Normalized Earnings Yield | 0.6145 |